UCB Data Reinforce Long-Term Promise For Weak Muscles Disorder - UCB SA NPV by UCB S.A. (OTC:UCBJF), UCB

UCB presents data showing rozanolixizumab & zilucoplan deliver sustained symptom relief for generalized myasthenia gravis (gMG).

Raccontata dabenzinga.com